Immunotherapy Update: What We’ve Learned
Immunotherapy has been called one of the most significant advances in cancer in decades. While this approach may work in some cancers, it is unclear
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
Immunotherapy has been called one of the most significant advances in cancer in decades. While this approach may work in some cancers, it is unclear
In between Sebago Lake and Casco Bay, there’s a Maine community where many people know about NET cancer and can even name someone who has
We are pleased to announce a $100,000 grant from the Karpus Family Foundation, Rochester, NY. The grant will help us discover insights into the life cycle
New Potential NET Treatment under Investigation It is hard for doctors to know which patients will respond to which therapies. New approaches in personalized medicine
David Van Bibber calls his neuroendocrine cancer diagnosis a blessing in disguise.it. Since his 2010 diagnosis at the age of 32, David’s priorities and perspectives have changed. As a result, he has invested more deeply in his health, his family, and his community. Now he is reaping the rewards of that investment and finding daily joy in his life.
Finding hope and motivation in a dark place, a young NET patient describes her life leading up and following peptide receptor radionuclide therapy (PRRT).
The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing a precision form of radiation therapy for NETs called Peptide Receptor
Two NETRF-funded researchers received Career Development Awards at the 2018 annual meeting of the American Society of Clinical Oncology (ASCO), one of the largest and
https://www.youtube.com/watch?v=k1906SABias The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing a precision form of radiation therapy for NETs called Peptide Receptor
Can an epigenetic enzyme under the right conditions contribute to the growth of cancer cells? If so, what happens if the enzyme is removed? Can